Latest AI and machine learning research in colon cancer for healthcare professionals.
Cancer is increasingly recognized as a metabolic disease with strong nutritional determinants. Recent advances in multi-omics technologies and artificial intelligence (AI), especially machine learning (ML), have enabled novel integrative frameworks to decode complex interactions among diet, metabolism, and tumor biology. To systematically synthesize evidence on how multi-omics and AI/ML approaches...
Post-translational modifications (PTMs) represent a fourth dimension of the genetic code, orchestrated by the Golgi apparatus and central to the biology of cancer. The prevailing paradigm of oncofetal reprogramming posits that cancer cells reactivate embryonic developmental programs to drive tumorigenesis; however, the lineage-specific nature of this reversion remains incompletely defined. This re...
Artificial intelligence (AI) has emerged as a transformative force in gastrointestinal (GI) endoscopy, offering enhancements in diagnostic accuracy, l...
Pancreatic cystic lesions (PCLs) are often discovered incidentally on imaging and may progress to pancreatic ductal adenocarcinoma (PDAC). PCLs have a...
Spatial transcriptomics technology remains resource-intensive and unlikely to be routinely adopted for patient care soon. This hinders the development...
Early-onset colorectal cancer (EOCRC) is rising rapidly, especially among populations at risk who experience disproportionate incidence and mortality....
Lung neuroendocrine tumours (NETs, also known as carcinoids) are rapidly rising in incidence worldwide but have unknown aetiology and limited therapeu...
Parkinson’s disease (PD) remains incurable, with a long preclinical phase currently undetectable by existing methods. In the largest proteomic study i...
Cancer is one of the leading lethal causes worldwide, with enormous impact on healthcare, economy and society. One of the main challenges of clinical ...
Early-onset colorectal cancer (EOCRC; <50 years) incidence is increasing most rapidly among Hispanic/Latino (H/L) populations. While the transforming ...
Each piece of cell-free DNA (cfDNA) has a length determined by the exact metabolic conditions in the cell it belonged to at the time of cell death. Th...
Pathology reporting of colorectal cancer (CRC) follows the International Collaboration on Cancer Reporting (ICCR) guidelines which define a set of 25 ...
Microsatellite instability (MSI) is a key biomarker for immunotherapy response and prognosis across multiple cancers, yet its identification from rout...
Cell-free DNA (cfDNA) methylation is a valuable biomarker in various cancers including colorectal cancer (CRC), but marker for both early diagnosis an...
The incidence of early-onset colorectal cancer (EOCRC; <50 years) continues to rise, with the most rapid increases observed among Hispanic/Latino (H/L...
Colorectal adenocarcinoma is caused in part by widespread epigenetic deregulation, yet the analysis of genome-wide DNA methylation of colorectal adeno...
Medical-image segmentation underpins quantitative diagnostics and research, yet state-of-the-art models remain task-specific and data-hungry. The rece...
Microsatellite instability (MSI) is a key biomarker in colorectal cancer (CRC). Accurate distinction between MSI and microsatellite stable (MSS) tumor...
Simulation models inform health policy decisions by integrating data from multiple sources and forecasting outcomes when there is a lack of comprehens...
Colorectal cancer (CRC) remains a major cause of cancer-related morbidity and mortality worldwide. Endoscopy and adenoma removal are effective in redu...